GAs with significant enrichment in systemic DLBCL included MLL2 (14.5% vs 31.4%, P ≤ .012), TP53 (11.6% vs 30.6%, P < .001), BCL2 (5.8% vs 31.8%, P < .001), CREBBP (5.8% and 17.9%, P ≤ .029), and TNFRSF14 (2.9% and 15.3%, P ≤ .012) (Fig. 2a and 2b). This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.